biostudies-literatureUnknown7(1)Chebbi P<h4>Introduction</h4>We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib.<h4>Methods</h4>This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded.<h4>Results</h4>During the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib weBMC rheumatology22https://www.ebi.ac.uk/biostudies/studies/S-EPMC10369741biostudies-literatureOccurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.PMC10369741Pinto BRao VKJanardana RTekkatte RChebbi PMahendranath KMPatil ASalanke MShobha VHaridas VKumar SfalseOccurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.<h4>Introduction</h4>We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib.<h4>Methods</h4>This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded.<h4>Results</h4>During the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib we2023-01-01T00:00:00Z2023 Jul2025-04-22T00:59:50.655Z2024-11-20T11:52:30.037ZS-EPMC103697413749610110.1186/s41927-023-00345-8